Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Stelis Biopharma — Q1 FY22 Earnings Presentation

21 slides from Strides Pharma Science's earnings presentation, Aug 6, 2021

  1. Slide 1: Exchange filing cover letter

    August 6, 2021 BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR Dear Madam/ Sir, Sub: Stelis Biopharma - Q1 FY22 Investor Update Plea

  2. Slide 2: An integrated biologics and vaccine player in the making

    An integrated biologics and vaccine player in the making Stelis Biopharma Limited , Q1FY22 Investor Update | August 06, 2021

  3. Slide 3: Introduction to Stelis

    Introduction to Stelis: A vertically integrated company with capabilities to take molecules from lab to market

  4. Slide 4: Stelis is a vertically integrated biopharma and vaccine company

    z Stelis is a vertically integrated biopharma and vaccine company ready to expand horizons Large Scale Infrastructure One Stop Capabilities Integrated vaccine suite ▸ 3 World class facilities with ▸ One-stop shop solution ▸ Dedicated vaccine facility to ~600,000 Square feet R&D from cell line and pr

  5. Slide 5: Integrated and flexible capabilities for biologics and vaccines

    z Integrated and flexible capabilities for a varied range of biologics and vaccines Dedicated R&D Setup Large Commercial Capability Standalone Vaccine facility 30,000 sq.ft. state-of-the-art process 300,000 sq. ft. integrated commercial 250,000 sq. ft. dedicated DS and DP development; pilot/scale-up

  6. Slide 6: Strategic oversight by Board of Directors

    z Strategic oversight by Board of Directors with rich experience across diverse industries Aditya Puri Vineeta Rai Arun Kumar Non-Executive Director & Independent Director & Founder Chairperson Chairperson of Audit Committee A first-generation entrepreneur with Former MD of HDFC Bank, India's an int

  7. Slide 7: Appointed Mark W. Womack as the New CEO and MD designate

    z Appointed Mark W. Womack as the New CEO and MD designate ▸ The Board of Stelis is delighted to appoint Mark as the CEO and MD designate of Stelis. He assumes the role with immediate effect and will be stationed at Stelis HQ in Bengaluru, India ▸ Mark will drive the growth strategy around the three

  8. Slide 8: Operating three differentiated domains in the global market

    z Operating three differentiated domains in the global market covering the entire value chain Global CDMO Services Vaccines Own Products End to end service provider A full services vaccines CDMO Building a portfolio of including process development, player with dedicated and advanced biosimilars, pe

  9. Slide 9: Global CDMO Services

    Global CDMO Services: Deep expertise and high speed of execution in product development and large-scale manufacturing

  10. Slide 10: Industry dynamics: Global CDMO opportunity

    z Leveraging our scientific capabilities with World Class infrastructure having large scale capacities 27b+ Our Vision Addressable Opportunity for Stelis To be the fully integrated global CDMO partner of choice for the global biopharma industry Our Mission S T E L I S S T R AT E G Y Driven by growth

  11. Slide 11: Large scale manufacturing for drug substance

    z Large Scale manufacturing offering speed and operation flexibility for drug substance(DS) Microbial Capabilities Mammalian capabilities Fermentation Cell Culture ▸ Stainless steel fermenters (Sartorius) of capacity 50L, 300L & ▸ 4 single-use trains up to 2000L 1000L ▸ Line-up: 50L→200L→2000L ▸ Hom

  12. Slide 12: State-of-the-art Drug Product infrastructure

    z State-of-the-art Drug Product(DP) Infrastructure With Significant Operational Flexibility Aseptic liquid filling Fully automatic Annual Capacity in all formats packaging line Presentation Equipment Working Range Status (2 shift basis) Cartridge Filling with pen Bausch Strobel filling Diameter 7mm

  13. Slide 13: Q1FY22 updates on global CDMO services business

    z Q1FY22 Updates on global CDMO services business Drug Product block commercialized with On track to receive all major regulatory Microbial drug substance block already healthy order book for the next 18-24 months approvals in FY22* validated and attracting commercial traction • Drug product block r

  14. Slide 14: Dedicated Suite for Vaccines

    Dedicated Suite for Vaccines : New suite developed as per BSL 2 requirements with integrated capabilities

  15. Slide 15: Industry dynamics: Global vaccine CDMO business

    z Building an integrated global vaccine CDMO business with large capacity and diverse capability 4b+ Our Vision Addressable Opportunity for Stelis To be the partner of choice in vaccines for global biopharmaceutical companies Our Mission S T E L I S S T R AT E G Y In last 5 years, multiple new produ

  16. Slide 16: New vaccine suite designed to produce over a billion doses a year

    z New vaccine suite designed to produce over a billion doses in a year Current Capabilities DS DP Design and Unique features ▸ Use of single use manifold systems to reduce the cross contamination between the batches. ▸ Nanoparticle fill finish capability Viral vector Yes Yes ▸ Manufacturing of Drug

  17. Slide 17: Q1FY22 updates on vaccines business

    z Q1FY22 Updates on vaccines business Update on Sputnik V Evaluating new vaccine partnerships • rAD5 and rAD26 components of the vaccine • Significant ongoing interest and discussions have been validated on the small scale to partner with other global players for vaccines manufacturing • Scale up of

  18. Slide 18: Own Products

    Own Products: Commercially attractive products with leading assets nearing approval stage

  19. Slide 19: Industry dynamics: biosimilar franchise

    z Scaling a compelling biopharma franchisee built on global scale and a niche product portfolio 65b+ Our Vision Addressable Opportunity for Stelis To become a globally recognized biosimilar business delivering efficient solutions to patients for improving lives. Our Mission S T E L I S S T R AT E G

  20. Slide 20: Targeting molecules in phase 1 with combined market size

    z Targeting 6 molecules in phase 1 with a combined market size of USD 40 billion Development Molecule Market Size ($b) Indication Latest Update Stage Filed in EU/ • EU file for MAA under review cycle, expected closure by Q4FY22 STLP001 ~2 Osteoporosis Phase 1 ready for • More than 20 companies are u

  21. Slide 21: Thank you

    Thank you For details, please visit www.stelisbiosource.com Stelis Biopharma Limited (Formerly Stelis Biopharma Private Limited) tar 1 Building, Opp. IIM Bangalore, Bilekahalli, Banngerghatta Road, Bangalore – 560 076, India Tel: +91 80 6784 0738 CIN: U74140KA2007PLC043095 For business and investor

Stelis Biopharma — Q1 FY22 Earnings Presentation on 6ix